Singapore's National Initiative for RNA Biology and its Applications

Singapore's National Initiative for RNA Biology and its Applications (NIRBA) is a national research platform launched on 24 March 2025. It is a foundational-research initiative: its purpose is to deepen understanding of RNA biology and create capabilities that can support later translation, rather than to provide a patient benefit or directly approve medicines (Prime Minister's Office Singapore, 24 March 2025). The initiative is led by Professor Ashok Venkitaraman and brings together researchers across Singapore's research and innovation ecosystem.

What NIRBA is intended to do

NIRBA has three linked objectives: build globally competitive peaks of excellence in RNA research, provide scientific foundations for translating and commercialising RNA-based products and services, and create operating mechanisms that allow researchers across Singapore's institutions to collaborate more effectively (Prime Minister's Office Singapore, 24 March 2025). Its four Innovation Clusters concern Asian genetic diversity and RNA-related disease, RNA modifications and host immunity, RNA delivery and distribution, and cellular mechanisms underlying personalised RNA medicine. The programme therefore spans basic biology, disease mechanisms, delivery, and eventual precision medicine; it is not synonymous with mRNA vaccines alone.

How it fits Singapore's biomedical ecosystem

NIRBA is designed to connect foundational research with existing national capabilities. The National Research Foundation (NRF) places this kind of foundational work within Singapore's wider RIE ecosystem. The launch speech identifies PRECISE-SG100K and Singapore's genomics and precision-medicine work as a base for studying Asian genetic diversity, while ASTAR's Nucleic Acid Therapeutics Initiative (NATi) provides a translational and commercialisation link for nucleic-acid therapeutics (Prime Minister's Office Singapore, 24 March 2025). ASTAR's NATi received S$97 million under RIE2025 for research, clinical translation, and commercialisation of RNA drugs and vaccines (Singapore Economic Development Board, 1 March 2024). NIRBA and NATi are complementary: NIRBA investigates biological mechanisms and targets, while NATi focuses more directly on therapeutic development and translation.

Research collaboration and limits of the programme

At launch, NUS, NTU, and A*STAR signed a Master Research Collaboration Agreement intended to make island-wide collaboration, intellectual-property management, and commercialisation of collaborative research easier (Prime Minister's Office Singapore, 24 March 2025). This collaborative structure is part of the wider RIE2030 direction toward cross-cutting Flagships and Grand Challenges. It does not mean that every RNA research proposal, therapy, or commercial product is funded by NIRBA, nor that the initiative itself is a medicines regulator or clinical service. Its public value is expected to arise through research outputs, shared resources, new targets, and stronger pathways to downstream development.